29 related articles for article (PubMed ID: 38483406)
1. The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients.
Ghesquières H; Krzisch D; Nicolas-Virelizier E; Kanoun S; Gac AC; Guidez S; Touati M; Laribi K; Morschhauser F; Bonnet C; Waultier-Rascalou A; Orsini-Piocelle F; André M; Fournier M; Morand F; Berriolo-Riedinger A; Burroni B; Damotte D; Traverse-Glehen A; Quittet P; Casasnovas O
Blood; 2024 Mar; 143(11):983-995. PubMed ID: 37979133
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphoma.
Purvis KN; Swanson HD; Niloy KK; Zhou Y; Panetta JC; Crews KR; Flerlage JE
Cancer Chemother Pharmacol; 2023 Jul; 92(1):1-6. PubMed ID: 37199744
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
[No Abstract] [Full Text] [Related]
4. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
Howell M; Gibb A; Radford J; Linton K
Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
[No Abstract] [Full Text] [Related]
5. Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution.
de Armas S; Huertas-Ayala C; Chan RY; Chi YY; Huh WW; Termuhlen A; Gaynon PS; Kovach AE; Doan A
Pediatr Blood Cancer; 2022 May; 69(5):e29601. PubMed ID: 35187850
[TBL] [Abstract][Full Text] [Related]
6. Aging Kairos: treating older Hodgkin patients.
Molin D
Blood; 2024 Mar; 143(11):943-945. PubMed ID: 38483406
[No Abstract] [Full Text] [Related]
7. [A suggested program of combined treatment of Hodgkin's disease in children].
Balwierz W; Armata J; Moryl-Bujakowska A; Strzeszyński J; Depowska T
Pol Tyg Lek; 1988 Dec; 43(50):1637-40. PubMed ID: 2476790
[No Abstract] [Full Text] [Related]
8. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Canellos GP
Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
[TBL] [Abstract][Full Text] [Related]
9. [Results of the treatment of lymphogranulomatosis].
Kholin AV
Ter Arkh; 1986; 58(2):143-7. PubMed ID: 2422774
[No Abstract] [Full Text] [Related]
10. Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?
Johnson PW
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):316-322. PubMed ID: 27913497
[TBL] [Abstract][Full Text] [Related]
11. Salvage therapy of advanced Hodgkin's disease. Critical appraisal of curative potential.
Buzaid AC; Lippman SM; Miller TP
Am J Med; 1987 Sep; 83(3):523-32. PubMed ID: 2444105
[TBL] [Abstract][Full Text] [Related]
12. [Treatment strategy of Hodgkin lymphoma].
Nagai H
Rinsho Ketsueki; 2014 Oct; 55(10):1941-51. PubMed ID: 25297759
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
